Skip to main content
SpringerLink
Log in

‘Extreme Duplication’ in the US FDA Adverse Events Reporting System Database

  • Correspondence
  • Published:
Drug Safety Aims and scope Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Table I

References

  1. Hauben M, Reich L. Communication of findings in pharmacovigilance: use of the term “signal” and the need for precision in its use. Eur J Clin Pharmacol 2005; 61: 479–80

    Article  PubMed  Google Scholar 

  2. CDER Guidance. Guidance for industry: guideline for postmarketing reporting of adverse drug experiences, 85D-0249 [online]. Available at URL: http://www.fda.gov/medwatch/REPORT/Mfg.htm [Accessed 2006 Dec 28]

  3. Preparing FOI Drug Safety Data for WebVDME Data Mining, Lincoln Technologies Inc., 2005

  4. Norén GN, Orre R, Bate A, et al. Duplicate detection in adverse drug reaction surveillance. Data Min Knowl Disc 2007; 14(3): 305–28

    Article  Google Scholar 

  5. Strom BL. Evaluation of suspected adverse drug reactions. JAMA 2005; 293(11): 1324–5

    Article  CAS  Google Scholar 

  6. Hauben M, Patadia V, Gerrits CM, et al. Data mining in pharmacovigilance: the need for a balanced perspective. Drug Saf 2005; 28(10): 835–42

    Article  PubMed  Google Scholar 

  7. Bate A, Edwards IR. Data mining in spontaneous reports. Basic Clin Pharmacol Toxicol 2006; 98(3): 324–30

    Article  PubMed  CAS  Google Scholar 

Download references

Acknowledgements

Pfizer markets/co-markets one or more of the drugs cited in this letter.

Author information

Authors and Affiliations

  1. Safety and Risk Management Strategy, Pfizer Inc, 235 E. 42nd Street, New York, New York, 10017, USA

    Manfred Hauben,  Lester Reich, James De Micco & Katherine Kim

  2. Department of Medicine, New York University School of Medicine, New York, New York, USA

    Manfred Hauben

  3. Department of Pharmacology, New York Medical College, Valhalla, New York, USA

    Manfred Hauben

  4. Departments of Community, New York Medical College, Valhalla, New York, USA

    Manfred Hauben

  5. Department of Preventive Medicine, New York Medical College, Valhalla, New York, USA

    Manfred Hauben

  6. School of Information, Computing, and Mathematics, Brunei University, West London, UK

    Manfred Hauben

Authors
  1. Manfred Hauben
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Lester Reich
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. James De Micco
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Katherine Kim
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Lester Reich.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Hauben, M., Reich, L., De Micco, J. et al. ‘Extreme Duplication’ in the US FDA Adverse Events Reporting System Database. Drug-Safety 30, 551–554 (2007). https://doi.org/10.2165/00002018-200730060-00009

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/00002018-200730060-00009

Keywords

Search

Navigation